Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitazalimab plus chemotherapy in previously untreated metastatic pancreatic ductal adenocarcinoma
2024-514905-79-00Phase 2Completed
- Sponsor
- Alligator Bioscience AB
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of mitazalimab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Alligator Bioscience AB. Primary endpoints: Incidence of dose-limiting toxicities and Objective response rate. Started Sep 2021; status: completed.
02
Drugs
mitazalimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-514905-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514905-79-00.